Telix Pharmaceuticals IPO Briefing - Melbourne

I warmly welcome you to attend a briefing and drinks event for Telix Pharmaceuticals Limited (ASX:TLX).

Andreas Kluge and I spent the last two years building the company and formally launched Telix in January 2017. The company's focus is the development and commercialisation of targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). We belive this field is one of the most exciting recent developments in oncology care and is attracting significant clinical and commercial interest.

Telix has bulit a pipeline of diagnostic and therapeutic programs in renal (kidney), prostate and brain (glioblastoma) cancer. The company has just filed a $50M fully-underwriten IPO - making it one of the largest life sciences IPOs in recent times. This financing will enable the company to reach several major development and commercial milestones over the next 24 months.

I look forward to providing an update and sharing a beverage.